Zhaoke Ophthalmology Limited （於英屬處女群島註冊成立並於開曼群島存續的有限公司） 兆科眼科有限公司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 （股份代號：6622） 兆科眼科的夥伴TENPOINT THERAPEUTICS, LTD. 接 獲FDA在美國 就BRIMOCHOL™ PF發出的批准 本 公 告 由 兆 科 眼 科 有 限 公 司（「本公司」）董 事 會（「董事會」）自 願 作 出。 本 公 司 董 事 會 欣 然 宣 佈，本 公 司 的 夥 伴Tenpoint Therapeutics, Ltd.（「Tenpoint」）已 接 獲 美 國 食 品 藥 品 監 督 管 理 局（「FDA」）批 准 商 業 化 卡 巴 膽 鹼 及 酒 石 酸 溴 莫 尼 丁 滴 眼 液（2.75%/0.1%）的 監 管 批 准。此 滴 眼 液 於 臨 床 試 驗 期 間 ...

消息面上，1月26日，兆科眼科宣布，将其核心老花眼治疗药物BRIMOCHOL PF在新加坡和越南的独家 商业化权利，分别授予新西兰的AFT Pharmaceuticals和日本的千寿制药。至此，兆科眼科其全球化商业 版图已延伸至韩国、澳洲、新西兰、泰国、印度尼西亚、台湾地区、新加坡和越南八个市场。 兆科眼科-B(06622)盘中涨超7%，截至发稿，涨3.44%，报3.61港元，成交额1143.15万港元。 根据协议，兆科眼科授予AFT在新加坡、授予千寿在越南的独家分销权。AFT Pharmaceuticals 是一家总 部位于新西兰的跨国制药公司，其商业模式核心在于在全球超过125个国家开发和授权产品。千寿制药 则是一家以研发为核心的日本私人制药公司，尤其在眼科领域深耕多年，旨在通过原创药品提升全球患 者的视力健康。 ...

每经AI快讯，兆科眼科-B(06622.HK)盘中涨超7%，截至发稿，涨3.44%，报3.61港元，成交额1143.15万 港元。 （文章来源：每日经济新闻） ...

Core Viewpoint - Zhaoke Ophthalmology-B (06622) has expanded its global commercialization rights for its core presbyopia treatment drug BRIMOCHOL™ PF to Singapore and Vietnam, enhancing its market presence in eight countries [1] Group 1: Company Developments - Zhaoke Ophthalmology has granted exclusive commercialization rights for BRIMOCHOL™ PF to AFT Pharmaceuticals in Singapore and to Santen Pharmaceutical in Vietnam [1] - The company’s global commercial footprint now includes South Korea, Australia, New Zealand, Thailand, Indonesia, Taiwan, Singapore, and Vietnam [1] Group 2: Partner Companies - AFT Pharmaceuticals is a multinational pharmaceutical company based in New Zealand, focusing on developing and licensing products in over 125 countries [1] - Santen Pharmaceutical is a Japan-based private pharmaceutical company with a strong emphasis on research and development, particularly in the ophthalmology sector [1]

Core Viewpoint - Zhaoke Ophthalmology-B (06622) has seen a stock price increase of over 5%, currently trading at 3.44 HKD, with a transaction volume of 1.707 million HKD, following the announcement of expanded partnerships for the commercialization of BRIMOCHOL™ PF in Singapore and Vietnam [1] Group 1: Partnerships and Commercialization - The company has expanded its partnership agreement with AFT Pharmaceuticals Limited to commercialize BRIMOCHOL™ PF in Singapore [1] - Zhaoke has also established a strategic partnership with Santen Pharmaceutical Co., Ltd. to commercialize the product in Vietnam [1] - AFT and Santen have been granted exclusive distribution rights in their respective markets, which include registration, import, promotion, distribution, marketing, and sales of BRIMOCHOL™ PF [1] Group 2: Product Information - BRIMOCHOL™ PF is a potential therapy for correcting near vision loss due to presbyopia, representing a core asset acquired through a partnership with Tenpoint Therapeutics, Ltd. [1] - The addition of AFT and Santen as commercialization partners marks the seventh and eighth partnerships for BRIMOCHOL™ PF, highlighting the company's commitment to global expansion [1]

每经AI快讯，兆科眼科-B(06622.HK)一度涨超5%，截至发稿涨4.56%，报3.44港元，成交额170.7万港 元。 ...

Core Viewpoint - The stock of Zhaoke Ophthalmology-B (06622) has increased by over 5%, reflecting positive market sentiment following the expansion of its partnership agreement with AFT Pharmaceuticals Limited for the commercialization of BRIMOCHOL PF in Singapore [1] Group 1: Partnership Expansion - Zhaoke Ophthalmology-B has expanded its partnership with AFT Pharmaceuticals to commercialize BRIMOCHOL PF in Singapore [1] - The company has also established a strategic partnership with Santen Pharmaceutical Co., Ltd. to commercialize the product in Vietnam [1] - AFT and Santen are now the seventh and eighth commercialization partners for BRIMOCHOL PF, indicating the company's commitment to global expansion [1] Group 2: Product Information - BRIMOCHOL PF is a potential therapy for correcting near vision loss due to presbyopia [1] - The product is a core asset acquired through a licensing agreement with Tenpoint Therapeutics, Ltd. [1]

Core Viewpoint - Zhaoke Ophthalmology-B (06622) has expanded its partnership with AFT Pharmaceuticals Limited for the commercialization of BRIMOCHOL™ PF in Singapore and established a strategic partnership with Santen Pharmaceutical Co., Ltd. for commercialization in Vietnam, indicating a strong commitment to global expansion [1] Group 1: Partnerships and Agreements - The company has granted exclusive distribution rights for BRIMOCHOL™ PF to AFT in Singapore and to Santen in Vietnam, which includes rights for registration, import, promotion, distribution, marketing, and sales in these markets [1] - AFT and Santen become the seventh and eighth commercialization partners for BRIMOCHOL™ PF, respectively, highlighting the company's strategy to broaden its market reach [1] Group 2: Product Information - BRIMOCHOL™ PF is a potential therapy aimed at correcting near vision loss due to presbyopia, representing a core asset acquired through a partnership with Tenpoint Therapeutics, Ltd. [1]

Core Viewpoint - Zhaoke Ophthalmology-B (06622) has seen a stock price increase of over 5%, currently trading at 3.44 HKD with a transaction volume of 1.707 million HKD, following the announcement of expanded partnerships for the commercialization of BRIMOCHOL PF in Singapore and Vietnam [1] Group 1: Partnerships and Agreements - The company has expanded its partnership agreement with AFT Pharmaceuticals Limited to commercialize BRIMOCHOL PF in Singapore [1] - Zhaoke has established a strategic partnership with Santen Pharmaceutical Co., Ltd. to commercialize the product in Vietnam [1] - AFT and Santen have been granted exclusive distribution rights for BRIMOCHOL PF in their respective markets, which includes rights for registration, import, promotion, distribution, marketing, and sales [1] Group 2: Product Information - BRIMOCHOL PF is a potential therapy for correcting near vision loss due to presbyopia, representing a core asset acquired through a partnership with Tenpoint Therapeutics, Ltd. [1] - The addition of AFT and Santen as commercialization partners marks the seventh and eighth partners for BRIMOCHOL PF, highlighting the company's commitment to global expansion [1]

Company News - China Power (02380.HK) expects a total consolidated electricity sales volume of 10.73105 million MWh by December 2025, a decrease of 2.31% year-on-year; the total annual electricity sales volume is approximately 126 million MWh, down 1.27% year-on-year [2] - Harbin Electric (01133.HK) anticipates a net profit attributable to shareholders of approximately RMB 2.65 billion for the fiscal year 2025, compared to RMB 1.686 billion in the previous year, mainly due to increased operating revenue and improved product profitability [2] - Singularity Guofeng (01280.HK) has entered into a GPU distribution cooperation agreement with Muxi Co., aiming to enter the domestic AI computing power market [2] - Dongyang Sunshine Pharmaceutical (06887.HK) has signed a strategic cooperation agreement with Shenzhen Jingtai to establish a joint venture for building an AI-driven drug research and development platform [2] - Weisheng Pharmaceutical-B (02561.HK) has received approval from the National Medical Products Administration for the marketing authorization application of injectable Long Pei growth hormone [2] - Kintor Pharmaceutical-B (02171.HK) issued a profit warning, expecting a net loss for 2025 to be reduced to no more than approximately RMB 120 million [2] - Zhaoke Ophthalmology-B (06622.HK) is advancing the commercialization process of BRIMOCHOL PF for treating presbyopia in Singapore and Vietnam through partnerships with AFT and Qianshou [2] Additional Company Developments - Heng Rui Medicine (01276.HK) has received a clinical trial approval notice for SHR-1049 injection [3] - Baolong Real Estate (01238.HK) has had its bond restructuring plan approved by the relevant bondholders' meeting [3] Strategic Partnerships - Yabo Technology Holdings (08279.HK) has entered into a technical service agreement with Hong Kong Gold Exchange Limited [4] - Future Data Group (08229.HK) has signed a strategic cooperation framework agreement with Linghe Culture [4] - Howey Group (00501.HK) plans to invest up to USD 50 million to subscribe for shares in Aixin Yuanzhi's initial public offering [4] Buyback Activities - Xiaomi Group-W (01810.HK) repurchased 3.9872 million shares for HKD 140 million, with a repurchase price ranging from HKD 35.04 to HKD 35.22 [5] - China Metallurgical Group (01618.HK) repurchased 9.011 million shares for HKD 16.9299 million, with a repurchase price of HKD 1.87 to HKD 1.88 [5] - Geely Automobile (00175.HK) repurchased 4.401 million shares for HKD 72.952 million, with a repurchase price ranging from HKD 16.43 to HKD 16.65 [6] - Reshape Energy (02570.HK) completed the placement of a total of 4.536 million placement shares, raising approximately HKD 258 million [6] - Kintor Pharmaceutical-B (09939.HK) saw an increase of 4.7 million shares by Chairman Tong Youzhi [6]